Analgesic Prescribing Patterns and Effectiveness of Pain Management among Advanced Cancer Patients receiving Palliative Care, at a Tertiary Care Teaching Hospital
International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)
DOI: 10.25258/ijcpr.18.5.65 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Asra Kichloo und 1 weiteren Autor:innen.
Themen: Palliativpflege, Schmerzmanagement, Onkologische Pflege
Abstract (Originalsprache)
Background
Pain is one of the most common and distressing symptoms experienced by patients with advanced cancer. Despite the availability of effective analgesic therapies and established guidelines such as the WHO analgesic ladder, cancer pain often remains inadequately controlled. Appropriate analgesic prescribing and regular pain assessment are essential components of palliative care aimed at improving patient comfort and quality of life. Aim and Objectives: To analyze the prescribing patterns of analgesic drugs and assess the effectiveness of pain management among advanced cancer patients receiving inpatient palliative care at a tertiary care teaching hospital. Materials and Methods: A cross-sectional observational study was conducted over a period of one year after obtaining Institutional Ethics Committee approval. A total of 200 patients diagnosed with advanced cancer and receiving inpatient palliative care in the oncology ward of a tertiary care teaching hospital were enrolled. Data regarding analgesic usage, WHO analgesic ladder utilization, pain intensity, pain relief scores, and patient experiences were collected using patient interviews, self-designed questionnaires, and review of medical records. Pain intensity was assessed using the Numeric Rating Scale (NRS).
Results
Among 200 patients included in the study, opioid analgesics were prescribed in 87% of patients, while non-opioid analgesics were used in 13% of cases. Morphine was the most commonly prescribed opioid followed by tramadol. Adjuvant analgesics such as pregabalin, were also prescribes to the patients for neuropathic pain management. According to the WHO analgesic ladder, 52% of patients received Step III medications. Despite widespread analgesic use, nearly 30% of patients reported inadequate pain relief. Delayed pain assessment, inadequate dose titration, and fear of opioid side effects were identified as major barriers to effective pain control.
Conclusion
The study demonstrated that opioid analgesics constitute the mainstay of cancer pain management in palliative care settings, with morphine being the most frequently prescribed drug. Although adequate pain relief was achieved in the majority of patients, a substantial proportion continued to experience uncontrolled pain. Regular pain assessment, individualized treatment strategies, appropriate opioid titration, and multidisciplinary interventions are essential for improving pain management outcomes in advanced cancer patients.
Zitieren
APA
Kichloo, A., & Choudhary, S. (2026). Analgesic Prescribing Patterns and Effectiveness of Pain Management among Advanced Cancer Patients receiving Palliative Care, at a Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.65
Vancouver
Kichloo A, Choudhary S. Analgesic Prescribing Patterns and Effectiveness of Pain Management among Advanced Cancer Patients receiving Palliative Care, at a Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.65
BibTeX
@article{Kichloo2026,
author = {Kichloo, Asra and Choudhary, Shabnam},
title = {Analgesic Prescribing Patterns and Effectiveness of Pain Management among Advanced Cancer Patients receiving Palliative Care, at a Tertiary Care Teaching Hospital},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {05},
doi = {10.25258/ijcpr.18.5.65}
}
EUVIMED